Welcome to the latest
edition of the JITC digest. October is an exciting and busy time here at
the journal as preparations are underway for the Society for Immunotherapy of
Cancer (SITC) Annual Meeting & Pre-Conference Programs, held this year at
the Boston Convention & Exhibition Center, November 8–12.
If you’ll be in Boston, be
sure to stop by the society booth at 12:30 p.m. EST on Thursday, November 10,
to say hello during our meet the editors session. On Friday, November 11 at
12:10 p.m., you can catch rapid oral presentations from this year’s JITC Best
Paper Award Winners along with an update from our editorial leadership during
session 207, "A Look at JITC's High-Impact Science." Finally,
we hope you will join us for a special JITC 10th Anniversary
Reception on Friday night at 7 p.m., held during the poster reception.
If you can’t make it to
Boston, you can always follow along from afar on JITC’s social media
channels. In addition to our Twitter feed, JITC now has a LinkedIn profile and we encourage you to
connect with us!
This month’s JITC digest
features three excellent original research articles and an intriguing short
report.
In a timely article given the ongoing viral vector backlog that is causing
months-long delays in treatment for some patients with hematological
malignancies, Katherine P Mueller et al describe CRISPR-Cas9-based
manufacturing of chimeric antigen receptor T cells enriched for memory
phenotypes.
Two papers provide novel insights into mechanisms of immune exclusion. Anqi Li
and colleagues demonstrate that therapeutic targeting of the cell surface
docking receptor that activates all major isoforms of latent transforming growth
factor beta improves
responses to anti-PD-1 in multiple relevant preclinical models. Carsten Krieg et
al identify a role for the complement anaphylatoxin C3a receptor in
resistance to anti-PD-1 and the establishment of the immunologically cold
colorectal cancer tumor microenvironment.
Finally, Kok Haw Jonathan Lim et al put
forward a short report with evidence that the extracellular plasma protein
secreted gelsolin is a negative regulator of immunogenic cell death in response
to chemotherapy, radiation, and targeted therapy.
Thank you for reading, and I hope to see some of you in Boston.
Best,
Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer
Editor-in-Chief, Journal for ImmunoTherapy of Cancer
No comments:
Post a Comment